The Frequency of <i>DPYD</i> c.557A>G in the Dominican Population and Its Association with African Ancestry

<b>Background/Objectives:</b> Genetic polymorphism of the dihydropyrimidine dehydrogenase gene (<i>DPYD</i>) is responsible for the variability found in the metabolism of fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, or tegafur. The <i>DPYD</i> ge...

Full description

Bibliographic Details
Published in:	Pharmaceutics
Main Authors:	Mariela Guevara, Carla González de la Cruz, Fernanda Rodrigues-Soares, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Subjects:	fluoropyrimidines <i>DPYD</i> cancer African ancestry pharmacogenetics
Online Access:	https://www.mdpi.com/1999-4923/17/1/8

Similar Items

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of <i>DPYD</i> Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study
by: Xando Díaz-Villamarín, et al.
Published: (2024-07-01)

Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
by: Almudena Gil-Rodríguez, et al.
Published: (2025-03-01)

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
by: Jonathan E. Knikman, et al.
Published: (2024-08-01)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023-09-01)

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger
by: Rocío Rosas-Alonso, et al.
Published: (2025-09-01)

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
by: Masashi Kanai, et al.
Published: (2023-04-01)

Upfront <i>DPYD</i> Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
by: Antoine Desilets, et al.
Published: (2022-01-01)

DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews
by: Sara Otero-Torres, et al.
Published: (2025-05-01)

Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines
by: Elena De Mattia, et al.
Published: (2024-12-01)

A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report
by: Anna Malekkou, et al.
Published: (2024-03-01)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
by: Paula Soria-Chacartegui, et al.
Published: (2021-11-01)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
by: Georgia Ragia, et al.
Published: (2023-09-01)

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol
by: Cassandra White, et al.
Published: (2024-11-01)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
by: A. Bignucolo, et al.
Published: (2023-05-01)

Investigation of Ivs14+1G>A Polymorphism of Dpyd Gene in a Group of Bosnian Patients Treated with 5-Fluorouracil and Capecitabine
by: Timur Cerić, et al.
Published: (2010-05-01)

Differences in <i>DPYD</i> Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study
by: Almudena Gil-Rodriguez, et al.
Published: (2025-04-01)

<i>DPYD</i> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
by: Theodore J. Wigle, et al.
Published: (2023-01-01)

Afro-Latin American Pharmacogenetics of <i>CYP2D6</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Dominicans: A Study from the RIBEF-CEIBA Consortium
by: Mariela Guevara, et al.
Published: (2024-10-01)

Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing
by: Lisa A. Varughese, et al.
Published: (2022-07-01)

Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients
by: Alessio Ardizzone, et al.
Published: (2024-09-01)

Implementation of DPYD testing in Bulgarian patients with cancer
by: Nelly Miteva-Marcheva, et al.
Published: (2024-12-01)

Pharmacogenomic tests in Oncology - finding the right dose
by: Jeziel Basso, et al.
Published: (2021-10-01)

Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
by: Guilherme Suarez-Kurtz
Published: (2021-10-01)

Commentary: The pharmacogenomic landscape of an Indigenous Australian population
by: Cassandra White, et al.
Published: (2024-05-01)

Extensive set of African ancestry-informative markers (AIMs) to study ancestry and population health
by: Samantha Boudeau, et al.
Published: (2023-02-01)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
by: Eiji Hishinuma, et al.
Published: (2022-06-01)

Near Miss or Standard of Care? <i>DPYD</i> Screening for Cancer Patients Receiving Fluorouracil
by: Lauren E. Winquist, et al.
Published: (2020-12-01)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
by: Anthi Maslarinou, et al.
Published: (2023-05-01)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
by: Nedal Bukhari, et al.
Published: (2021-07-01)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
by: David K. Lau, et al.
Published: (2023-04-01)

Apothecial Ancestry, Evolution, and Re-Evolution in <i>Thelebolales</i> (<i>Leotiomycetes, Fungi</i>)
by: Luis Quijada, et al.
Published: (2022-04-01)

Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients
by: Mai Mehanna, et al.
Published: (2022-08-01)

Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study
by: Vasileios Fragoulakis, et al.
Published: (2023-11-01)

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
by: Seid Hamzic, et al.
Published: (2020-11-01)

Population-Specific Distribution of TPMT Deficiency Variants and Ancestry Proportions in Ecuadorian Ethnic Groups: Towards Personalized Medicine
by: Gallardo-Cóndor J, et al.
Published: (2023-11-01)

All‐Cause, Cardiovascular, and Stroke Mortality Among Foreign‐Born Versus US‐Born Individuals of African Ancestry
by: Alain Lekoubou Looti, et al.
Published: (2023-05-01)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
by: Ursina B. M. Begré, et al.
Published: (2022-05-01)

Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant
by: Amy de Haar-Holleman, et al.
Published: (2024-09-01)

Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer
by: N. N. Timoshkina, et al.
Published: (2019-01-01)